EPISODE · Jan 31, 2025 · 20 MIN
30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 4 Quality by Design (QbD) – Fundamentals SUPPLEMENT
from Cannabinoid and Psychedelic Pharmacology and Drug Development
This podcast episode explores the fundamental differences between synthetic single-molecule compounds and natural extracts in the context of cannabinoids and psychedelics. The discussion delves into the complexities and challenges of working with natural extracts, including concepts like residual complexity, batch variability, cultivar stability, and polypharmacy. The episode then introduces Quality by Design (QBD) as a systematic approach to managing these challenges, explaining how this scientific methodology helps create more consistent and reliable products. The conversation concludes with insights into personalized medicine and the future potential of these compounds in therapeutic applications.
Embed this episode
NOW PLAYING
30 Day FDA Drug Development in Cannabinoid and Psychedelic Spaces - Day 4 Quality by Design (QbD) – Fundamentals SUPPLEMENT
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.